We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc. announced today the Government of Quebec will continue to provide public funding of JARDIANCE® (empagliflozin), SYNJARDY® (a single-pill combination of empagliflozin and metformin), and TRAJENTA
Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc. announced today the Government of Quebec will continue to provide public funding of JARDIANCE® (empagliflozin), SYNJARDY® (a single-pill combination of empagliflozin and metformin), and TRAJENTA